enGene Holdings Inc. (NASDAQ:ENGNW – Get Free Report) shares fell 6.3% during mid-day trading on Tuesday . The stock traded as low as $0.71 and last traded at $0.75. 2,006 shares were traded during trading, a decline of 77% from the average session volume of 8,753 shares. The stock had previously closed at $0.80.
enGene Trading Down 6.3%
The firm has a fifty day moving average price of $0.73 and a 200-day moving average price of $0.75.
enGene Company Profile
enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.
Read More
- Five stocks we like better than enGene
- What Are Dividends? Buy the Best Dividend Stocks
- EA’s $55 Billion Deal Spurs a Shake-Up in the Gaming Sector
- Quiet Period Expirations Explained
- These Are the 3 Hottest Sectors for Q3 Earnings Growth
- What is a Special Dividend?
- AMD Could Double From Here—Thanks to Its Blockbuster OpenAI Deal
Receive News & Ratings for enGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for enGene and related companies with MarketBeat.com's FREE daily email newsletter.
